Subscribe to our email list
Letter from the Director: CTTC eclipses major milestone
Letter from the Director: CTTC eclipses major milestone
Share this:
http://www.vanderbilt.edu/cttc/
http://www.vanderbilt.edu/cttc/about http://www.vanderbilt.edu/cttc/faculty-inventors http://www.vanderbilt.edu/cttc/industry-licensees http://www.vanderbilt.edu/cttc/new-venture
Letter from the Director: 
CTTC reaches milestone, eclipses 100 deals
It’s not often that a service-oriented unit is able to celebrate audacious achievement, but we at the Center for Technology Transfer and Commercialization are doing just that. The Center ended FY 2014 with 101 licensing transactions with industry partners, nearly 20 more than our record total, set last year.  
In my nearly 20-year history in academic technology commercialization, I have never been involved with a program that even came close to this level of deal flow.  And this was accomplished AFTER applying more rigor to what we count as a bone fide licensing transaction.  Several years ago, to be consistent with national counting standards, CTTC stopped counting transactions with an expected lifetime earning potential below a certain threshold toward our annual licensing totals.
And though the number of licenses executed is an important indication of programmatic success, so too is the type and quality of such licenses; not all licenses are created equal.  Some transactions, such as research materials licenses and end-user software licenses, create short-term value. Others, namely patent and software licenses with royalty obligations on product sales, offer opportunity for long-term value creation.  In FY14, not only did Vanderbilt’s total licensing numbers reach new heights, but we also saw a rise in the number of high value potential, royalty-bearing licenses. 
So while there are clear short-term benefits to achieving such a high volume of licenses, the real benefits will be realized 10 years down the line when technologies licensed in FY14 result in products on the market.  These products will generate recurring revenues that are distributed to the inventors and their designated schools, departments, centers and institutes, all to support our academic research mission and to reward Vanderbilt inventors for their contributions to new innovations that impact society.
To learn more about our FY14 metrics, see the latest issue of our newsletter Driving Innovation Forward, featuring imaging institute researcher Will Grissom, Ph.D., assistant professor biomedical engineering.

Alan Bentley
Assistant Vice Chancellor for Technology Commercialization and Intellectual Property Protection 
Driving Innovation Forward, Issue 3
Weekly interactions: 
CTTC staff members work diligently to manage all disclosures and requests in a timely manner. Below is a sampling of the activity that has taken place in our office over the past few weeks:
Executed a transaction with a large biotech company to leverage BioVU, Vanderbilt’s massive DNA database.  
Executed an option agreement for novel insect repellent compounds developed in the lab of Larry Zwiebel from the Department of Biological Sciences. Also, held a teleconference with a human and animal health company to discuss additional markets for these compounds.
Met with industry contacts and introduced them to Vanderbilt’s technologies and capabilities at the Association of University Technology Managers regional conference.
Attended the Southeastern Region Technology Transfer Directors’ meeting in Atlanta, as well as the SEC Technology Transfer Directors’ meeting.
Submitted a proposal for an I-Corps Sites grant, worth $100,000 per year for three years to help develop nascent companies and their technologies.
Discussed a collaboration agreement with a mid-sized publishing company around a joint proposal for funding with David Dickinson of Peabody College. 
Served on a panel at a regional meeting of technology transfer professionals invention evaluation, assessment and communication with inventors. 
Executed a license with a startup company for drug screening technology developed in the laboratory of Dave Weaver in the Department of Pharmacology
Presented information about intellectual property and technology commercialization at the new faculty meeting.
Attended the 2014 BIO International Conference – met with dozens of industry representatives to establish relationships and pitch Vanderbilt technologies.
Meet  Featured Inventor Will Grissom, Ph.D., assistant professor in biomedical engineering
Featured Inventor: Will Grissom, Ph.D.
Vanderbilt sends 2nd team to NSF I-Corps program
CTTC New Ventures Manager, Rigved Joshi, served as a mentor to Team Filtergraph at the University of Michigan, Ann Arbor cohort for the National Science Foundation Innovation Corps program. The three-day kick off event consisted of 22 I-Corps Team winners from across the U.S. The program is aimed at accelerating commercialization and customer discovery for promising university related technologies and consists of an intensive and immersive eight-week curriculum. This is the second Vanderbilt team to begin the program. Two additional teams were selected for 2014 fall cohorts. More about NSF I-Corps
Team Filtergraph
Pictured above: Keivan Stassun, Ph.D., professor of astronomy & physics, Rachel-Chloe Gibbs, research associate, and Dan Burger, research assistant.
FY 2015 Statistics
Year-to-Date
Agreements administered by CTTC 
 
Licenses*/Options
Material Transfer
54
Confidentiality
3
IP-related activities 
 
Invention Disclosures 
6
U.S. Patents Issued
7
*includes end-user license agreements
1207 17th Ave South | Suite 105 | Nashville, TN 37212
p 615.343.2430 | f 615.343.4419 | cttc@vanderbilt.edu | www.vanderbilt.edu/cttc
http://www.linkedin.com/groups/Vanderbilt-Center-Technology-Transfer-Commercialization-4139396?gid=4139396&trk=hb_side_g http://www.youtube.com/vanderbiltcttc http://twitter.com/#!/VanderbiltCTTC https://www.facebook.com/VanderbiltCTTC?v=app_197602066931325&app_data=%26wlbb%3D1%26fanmode%3Dnon http://www.vanderbilt.edu/cttc/

This email was sent to . To ensure that you continue receiving our emails,
please add us to your address book or safe list.
manage your preferences | opt out using TrueRemove®
Got this as a forward? Sign up to receive our future emails.

powered by emma